Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses

Abstract

Viruses that replicate in the human respiratory mucosa without infecting systemically, including influenza A, SARS-CoV-2, endemic coronaviruses, RSV, and many other “common cold” viruses, cause significant mortality and morbidity and are important public health concerns. Because these viruses generally do not elicit complete and durable protective immunity by themselves, they have not to date been effectively controlled by licensed or experimental vaccines. In this review, we examine challenges that have impeded development of effective mucosal respiratory vaccines, emphasizing that all of these viruses replicate extremely rapidly in the surface epithelium and are quickly transmitted to other hosts, within a narrow window of time before adaptive immune responses are fully marshaled. We discuss possible approaches to developing next-generation vaccines against these viruses, in consideration of several variables such as vaccine antigen configuration, dose and adjuventation, route and timing of vaccination, vaccine boosting, adjunctive therapies, and options for public health vaccination polices.

Abstract

Despite the successful deployment of vaccines during the SARS-CoV2 pandemic, viruses replicating in the respiratory mucosal environment continue to present a particular challenge for developing effective vaccines with strong protection. Morens et al. discuss approaches that need to be prioritized for the development of next-generation vaccines against these viruses.